AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 23
- Registration Number
- NCT00787410
AZD8075 Single Ascending Dose Study
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2010-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 72
- Registration Number
- NCT00787072
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Survey to Describe Impact of Reflux Disease on Everyday Life in GERD Patients Before and After 4 Weeks Treatment.
Completed
- Conditions
- Gastroesophageal Reflux Disease
- First Posted Date
- 2008-11-06
- Last Posted Date
- 2010-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2091
- Registration Number
- NCT00786773
- Locations
- 🇻🇳
Research Site, Thai binh, Vietnam
AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2014-10-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00785915
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2015-01-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 273
- Registration Number
- NCT00785408
- Locations
- 🇺🇸
Research Site, Olympia, Washington, United States
NIS-observe Treatment Efficacy in Maintaining Symptoms Control in Moderate/Severe Asthma With Symbicort SMART
Completed
- Conditions
- Moderate/Severe Asthma
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2010-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1182
- Registration Number
- NCT00785733
- Locations
- 🇷🇴
Research Site, Zalau, Romania
Retrospective Treatment Pattern Survey for the Patient With and Without History of Stroke
Completed
- Conditions
- Hypertension
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT00785057
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
ATAC - Quality of Life Sub-Protocol
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2009-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 308
- Registration Number
- NCT00784680
ATAC - Bone Density Sub-Protocol
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2009-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 308
- Registration Number
- NCT00784940
ATAC - Pharmacokinetics (PK) Sub-Protocol
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2009-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 9358
- Registration Number
- NCT00784862
© Copyright 2025. All Rights Reserved by MedPath